IL4 and cancer: In cancer, considered to be a Th2-dominant disease with excess of IL-4, IL-5, IL-10, and TGF-β production, a therapeutically driven shift back toward the Th1 profile is of interest, as it might correlate with immune and perhaps clinical recovery (Lucey et al., 1996).